Format

Send to:

Choose Destination
See comment in PubMed Commons below
Virology. 2014 May;456-457:300-9. doi: 10.1016/j.virol.2014.03.018. Epub 2014 Apr 24.

Human pegivirus (GB virus C) NS3 protease activity inhibits induction of the type I interferon response and is not inhibited by HCV NS3 protease inhibitors.

Author information

  • 1Saint Louis University School of Medicine, Department of Molecular Microbiology and Immunology, St. Louis, MO, USA; Saint Louis University School of Medicine, Department of Internal Medicine, Division of Infectious Diseases, Allergy & Immunology, St. Louis, MO, USA. Electronic address: chowdhay@slu.edu.
  • 2Saint Louis University School of Medicine, Department of Molecular Microbiology and Immunology, St. Louis, MO, USA. Electronic address: tavisje@slu.edu.
  • 3Saint Louis University School of Medicine, Department of Molecular Microbiology and Immunology, St. Louis, MO, USA; Saint Louis University School of Medicine, Department of Internal Medicine, Division of Infectious Diseases, Allergy & Immunology, St. Louis, MO, USA; Saint Louis Veterans Administration Medical Center, St. Louis, MO, USA. Electronic address: georgesl@slu.edu.

Abstract

We previously found that human pegivirus (HPgV; formerly GBV-C) NS3 protease activity inhibits Human Immunodeficiency Virus (HIV) replication in a CD4+ T cell line. Given the protease׳s similarity to the Hepatitis C virus (HCV) NS3 protease, we characterized HPgV protease activity and asked whether it affects the type I interferon response or is inhibited by HCV protease antagonists. We characterized the activity of proteases with mutations in the catalytic triad and demonstrated that the HCV protease inhibitors Telaprevir, Boceprevir, and Danoprevir do not affect HPgV protease activity. HPgV NS3 protease cleaved MAVS but not TRIF, and it inhibited interferon responses sufficiently to enhance growth of an interferon-sensitive virus. Therefore, HPgV׳s inhibition of the interferon response could help promote HPgV persistence, which is associated with clinical benefits in HIV-infected patients. Our results also imply that HCV protease inhibitors should not interfere with the beneficial effects of HPgV in HPgV/HCV/HIV infected patients.

Published by Elsevier Inc.

KEYWORDS:

GB Virus-C; Hepatitis C virus; Human pegivirus; MAVS; Protease inhibitors; Serine protease; TRIF; Type I interferon

PMID:
24889249
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk